← Back to Search

Other

mHRME (Mobile High resolution microendoscope) for Anal Squamous Intraepithelial Lesions

Phase 1 & 2
Waitlist Available
Led By Sharmilla Anandasabapathy, MD
Research Sponsored by Baylor College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1
Awards & highlights

Study Summary

This trial is testing a new, portable microendoscope that takes subcellular images of the anal epithelium to look for changes associated with neoplasia (abnormal tissue growth). The investigators hypothesis is that this 'optical' approach will be more efficient and have a greater clinical impact than the standard of HRA (High resolution anoscopy)-guided biopsy.

Eligible Conditions
  • Anal High-Grade Squamous Intraepithelial Lesions

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Performance characteristics: Sensitivity (SN), Specificity (SP), positive predictive value (PPV) and negative predictive values (NPV)
Secondary outcome measures
Procedure efficiency
Procedure time

Trial Design

1Treatment groups
Experimental Treatment
Group I: mHRMEExperimental Treatment3 Interventions
5-10 ml of proflavine hemisulfate (0.01%) will be applied on the anal epithelium. The mHRME will then be inserted and imaging of abnormal tissues will be performed. This is a single-arm study where all subjects will receive both standard of care HRA (High resolution anoscopy) and experimental mHRME imaging.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
mHRME (Mobile High resolution microendoscope)
2019
Completed Phase 2
~170
Proflavine Hemisulfate
2009
Completed Phase 2
~210
High resolution anoscopy
2019
Completed Phase 2
~170

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

William Marsh Rice UniversityOTHER
45 Previous Clinical Trials
27,692 Total Patients Enrolled
M.D. Anderson Cancer CenterOTHER
2,966 Previous Clinical Trials
1,804,620 Total Patients Enrolled
University of California, San FranciscoOTHER
2,500 Previous Clinical Trials
15,236,310 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the FDA recognize mHRME as a safe and effective medical device?

"The safety of mHRME was given a 2. This is due to the fact that, while there are Phase 2 trials underway testing its safety, there are no such studies investigating whether or not the mobile high resolution microendoscope is effective."

Answered by AI

Is this research project still recruiting individuals?

"That is correct. The information available on clinicaltrials.gov indicates that this study, which was originally posted on 7/1/2019, is still recruiting patients. They are looking for 200 individuals from 2 separate locations."

Answered by AI

How many people are allowed to be in this trial at any given time?

"That is correct. The clinical trial in question, as reflected on the website clinicaltrials.gov, appears to be currently recruiting patients. This specific study was first published on 7/1/2019 and was most recently updated on 9/7/2021. They are looking for 200 volunteers at 2 different locations."

Answered by AI
~28 spots leftby Apr 2025